Georgios Katsipis

Dr. Georgios Katsipis

Laboratory of Neurodegenerative Diseases, Aristotle University, Thessaloníki, Kentrikí Makedonía, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
Georgios KatsipisGeorgios Katsipis
Georgios Katsipis
ETElena E. Tzekaki
Elena E. Tzekaki
MTMagda Tsolaki
Magda Tsolaki
APAnastasia Pantazaki
Anastasia Pantazaki

1 August 2021 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
EAEleni G. Andreadou
Eleni G. Andreadou
Georgios KatsipisGeorgios Katsipis
Georgios Katsipis
MTMagda Tsolaki
Magda Tsolaki
APAnastasia Pantazaki
Anastasia Pantazaki

13 January 2023 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
Georgios KatsipisGeorgios Katsipis
Georgios Katsipis
APAnastasia Pantazaki
Anastasia Pantazaki
Staphylococcus aureus biofilms are implicated in hospital infections due to elevated antibiotic and host immune system resistance. Molecular components of cell wall including amyloid proteins, peptidoglycans (PGs), and lipoteichoic acid (LTA) are crucial for biofilm formation and tolerance of methicillin-resistant S. aureus (MRSA). Significance of alkaline phosphatases (ALPs) for biofilm formation has been recorded. Serrapeptase (SPT), a protease of Serratia marcescens, possesses antimicrobial properties similar or superior to those of many antibiotics. In the present study, SPT anti-biofilm activity was demonstrated against S. aureus (ATCC 25923, methicillin-susceptible strain, methicillin-susceptible S. aureus (MSSA)) and MRSA (ST80), with IC50 values of 0.67 μg/mL and 7.70 μg/mL, respectively. SPT affected bacterial viability, causing a maximum inhibition of − 46% and − 27%, respectively. Decreased PGs content at [SPT] ≥ 0.5 μg/mL and ≥ 8 μg/mL was verified for MSSA and MRSA, respectively. In MSSA, LTA levels decreased significantly (up to − 40%) at lower SPT doses but increased at the highest dose of 2 μg/mL, a counter to spectacularly increased cellular and secreted LTA levels in MRSA. SPT also reduced amyloids of both strains. Additionally, intracellular ALP activity decreased in both MSSA and MRSA (up to − 85% and − 89%, respectively), while extracellular activity increased up to + 482% in MSSA and + 267% in MRSA. Altered levels of DING proteins, which are involved in phosphate metabolism, in SPT-treated bacteria, were also demonstrated here, implying impaired phosphorus homeostasis. The differential alterations in the studied molecular aspects underline the differences between MSSA and MRSA and offer new insights in the treatment of resistant bacterial biofilms. Key points: • SPT inhibits biofilm formation in methicillin-resistant and methicillin-susceptible S. aureus. • SPT treatment decreases bacterial viability, ALP activity, and cell wall composition. • SPT-treated bacteria present altered levels of phosphate-related DING proteins. Graphical

6 November 2020 in BioMetals
Verified
Journal Article
Closed access
PDF file
Dimitris MatiadisDimitris Matiadis
Dimitris Matiadis
MKMaria Karagiaouri
Maria Karagiaouri
BMBarbara Mavroidi
Barbara Mavroidi
KNKatarzyna E. Nowak
Katarzyna E. Nowak
Georgios KatsipisGeorgios Katsipis
Georgios Katsipis
MSMarina Sagnou
Marina Sagnou

23 September 2023 in Applied Microbiology and Biotechnology
Verified
Journal Article
Open access
PDF file
Georgios KatsipisGeorgios Katsipis
Georgios Katsipis
DADimitrios I. Avgoulas
Dimitrios I. Avgoulas
GGGeorge D. Geromichalos
George D. Geromichalos
MPMaria Petala
Maria Petala
APAnastasia Pantazaki
Anastasia Pantazaki
Pseudomonas aeruginosa is an emerging threat for hospitalized and cystic fibrosis patients. Biofilm, a microbial community embedded in extracellular polymeric substance, fortifies bacteria against the immune system. In biofilms, the expression of functional amyloids is linked with highly aggregative, multi-resistant strains, and chronic infections. Serrapeptase (SPT), a protease possessing similar or superior anti-microbial properties with many antibiotics, presents anti-amyloid potential. However, studies on the employment of SPT against Pseudomonas biofilms and Fap amyloid, or the possible mechanisms of action are scarce. Here, SPT inhibited biofilm formation of P. aeruginosa ATCC 27853 on both plastic and glass surfaces, with an IC50 of 11.26 µg/mL and 0.27 µg/mL, respectively. The inhibitory effect of SPT on biofilm was also verified with optical microscopy of crystal violet-stained biofilms and with confocal microscopy. Additionally, SPT caused a dose-dependent decrease of bacterial viability (IC50 of 3.07 µg/mL) as demonstrated by MTT assay. Reduction of bacterial functional amyloids was also demonstrated, employing both fluorescence microscopy with thioflavin T and photometrical determination of Congo-red-positive compounds. Both viability and functional amyloids correlated significantly with biofilm inhibition. Finally, in silico molecular docking studies provided a mechanistic insight into the interaction of SPT with FapC or FapD, proving that both peptides are possible targets of SPT. These results offer new insights into the biofilm formation of P. aeruginosa and potentiate the involvement of SPT in the prevention and eradication of Pseudomonas biofilms. Graphical Key points: • Serrapeptase inhibits biofilm formation of P. aeruginosa on plastic and glass. • Biofilm inhibition correlated with reduced viability and functional amyloid levels. • In silico studies indicated that serrapeptase may target FapC and FapD peptides.

30 July 2022 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
EHE. Halevas
E. Halevas
SMS. Matsia
S. Matsia
AHA. Hatzidimitriou
A. Hatzidimitriou
EGE. Geromichalou
E. Geromichalou
TPT.A. Papadopoulos
T.A. Papadopoulos
Athanasios SalifoglouAthanasios Salifoglou
Athanasios Salifoglou